Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 8:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 91 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sickle Cell Anemia Crisis Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis

NCT03296345
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Crisis
Interventions
Ketamine
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
10 Years to 25 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 5, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

NCT01419977
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Placebo, Dalteparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 5, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Results available

Pain Management in Children and Young Adults With Sickle Cell Disease

NCT01954927
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 20 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 5, 2026, 8:41 AM EDT
Recruiting No phase listed Observational

Natural History of Sickle Cell Disease

NCT00081523
View directory record Official record
Conditions
Pain Crisis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 90 Years
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 5, 2026, 8:41 AM EDT
Terminated Phase 2 Interventional

Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate

NCT00040456
View directory record Official record
Conditions
HEMOGLOBIN SC DISEASE
Interventions
Mg Pidolate, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 5, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Results available

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

NCT03474965
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 5, 2026, 8:41 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

NCT02417298
View directory record Official record
Conditions
Pain, Sickle Cell Disorder
Interventions
Normal saline, Ketamine
Drug
Lead sponsor
Billy Sin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 5, 2026, 8:41 AM EDT
Completed Phase 1 Interventional

Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension

NCT00023296
View directory record Official record
Conditions
Sickle Cell Anemia, Pulmonary Hypertension
Interventions
Nitric Oxide, INO Pulse - NO Delivery System
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 5, 2026, 8:41 AM EDT
Completed Phase 3 Interventional

Evaluation of Repeat Administration of Purified Poloxamer 188

NCT02449616
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
MST-188
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
4 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
9
States / cities
San Diego, California • Fort Myers, Florida • Hollywood, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 5, 2026, 8:41 AM EDT
Terminated Phase 4 Interventional Results available

Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease

NCT00115336
View directory record Official record
Conditions
Hematologic Diseases, Anemia, Sickle Cell
Interventions
Intravenous Ketorolac, Ibuprofen
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 5, 2026, 8:41 AM EDT
Terminated Phase 3 Interventional

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

NCT05348915
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 5, 2026, 8:41 AM EDT
Completed Phase 2 Interventional

Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis

NCT02411708
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
SANGUINATE, Placebo
Drug
Lead sponsor
Prolong Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Hollywood, Florida • Tampa, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 5, 2026, 8:41 AM EDT
Terminated Phase 1Phase 2 Interventional

L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

NCT04852172
View directory record Official record
Conditions
Acute Vaso Occlusive Crisis (VOC)
Interventions
L-citrulline, D5 1/2NS
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 5, 2026, 8:41 AM EDT
Withdrawn Phase 4 Interventional

Ketamine Infusion for Sickle Cell Pain Crisis

NCT04005209
View directory record Official record
Conditions
Anemia; Sickle-Cell, With Crisis, Acute Pain
Interventions
Ketamine, Pain management
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 5, 2026, 8:41 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 5, 2026, 8:41 AM EDT
Completed Not applicable Interventional

Sickle Cell, Pain and Mediterranean Diet

NCT06886477
View directory record Official record
Conditions
Sickle Cell, Sickle Cell Disease, Sickle Cell Disease Without Crisis, Mediterranean Diet
Interventions
Mediterranean Diet, Usual Diet
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 5, 2026, 8:41 AM EDT
Terminated Phase 3 Interventional

Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED

NCT04150757
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis, Ketamine, Intranasal Ketamine, Analgesia
Interventions
Intranasal ketamine
Drug
Lead sponsor
Abigail Nixon
Other
Eligibility
3 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 5, 2026, 8:41 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis

NCT04614610
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis, Pain, Acute
Interventions
Lidocaine Iv, Placebo
Drug
Lead sponsor
Community Medical Center, Toms River, NJ
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Long Branch, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 5, 2026, 8:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Microvascular Blood Flow in Sickle Cell Anemia

NCT01566890
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
regadenoson infusion with contrast-enhanced ultrasound, contrast-enhanced ultrasound
Drug · Procedure
Lead sponsor
Versiti Blood Health
Other
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 5, 2026, 8:41 AM EDT
Completed Phase 2 Interventional

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

NCT01119833
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
Interventions
GMI-1070, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
12 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Berkeley, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 5, 2026, 8:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

NCT00834899
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 5, 2026, 8:41 AM EDT
Completed Phase 1 Interventional

Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease

NCT00095472
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
L-NMMA, Sodium Nitrite
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 5, 2026, 8:41 AM EDT
Withdrawn Phase 2 Interventional

Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

NCT01932554
View directory record Official record
Conditions
Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain, Hemoglobin SS Disease With Vasoocclusive Crisis, Other Sickle Cell Disease With Vaso-Occlusive Pain, Hemoglobin SS Disease With Crisis
Interventions
Abciximab, Placebo, Intravenous hydration, Ibuprofen, Parenteral narcotic, Incentive spirometry, Supplemental oxygen
Drug · Other
Lead sponsor
St. Louis University
Other
Eligibility
5 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 5, 2026, 8:41 AM EDT
Completed Phase 2 Interventional

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

NCT04987489
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Etavopivat tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Cerritos, California • Los Angeles, California • Oakland, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 5, 2026, 8:41 AM EDT